CareLit Fachartikel
Phosphoramidon, a novel matrix metalloproteinase inhibitor, inhibits significantly tumor growth independently of the application route (intraperitoneal [i.p.] versus intravenous […
A Hribaschek, F Meyer, K Ridwelski, P Habermann, H Lippert · Zeitschrift für Gastroenterologie · 2006 · Heft 04
Dokument
965166
CareLit-ID
Jahr
2006
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Introduction: Occurrence of peritoneal carcinomatosis remains still an unsolved problem in gastrointestinal cancer. Over the last years, novel antineoplastic substances such as matrix metalloproteinase (MMP) inhibitors have been investigated in animal models to achieve a decrease of tumor growth. The aim of the study was to determine whether i) Phosphoramidon, an MMP inhibitor, can prevent or diminish i.p. tumor growth, and ii) whether direct i.p. administration of Phosphoramidon is superior to the i.v. route. Methods: In WAG rats (weight, 250–300g) devided in 2 groups, peritoneal carcinomatosis was induced by t…
Schlagworte
Tumor
After
Germany
Adenocarcinoma
Ascites
Zeitschrift für Gastroenterologie
